Showing results (91-100 of 127) with videos related to
Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network studyF Anthony Greco, Howard A Burris, Sharlene Litchy, et al.The Oncologist|October 27, 2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trialF Anthony Greco, Dana S Thompson, Lisa H Morrissey, et al.Cancer|January 23, 2015
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trialJohn D Hainsworth, Gedske Daugaard, Thierry Lesimple, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian, Howard A Burris, Suzanne Jones, et al.Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.The Oncologist|October 29, 2002
A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignanciesSuzanne F Jones, F Anthony Greco, John D Hainsworth, et al.Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.Cancer|September 1, 2005
A Phase I trial of protracted oral fixed-dose temozolomideSuzanne F Jones, F Anthony Greco, Victor G Gian, et al.Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.Clinical Lung Cancer|May 5, 2010
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, Dana S Thompson, et al.Pageof 13